Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) have earned an average recommendation of “Buy” from the eight analysts that are covering the firm. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $12.43.

ARGS has been the topic of a number of research reports. Zacks Investment Research raised shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Monday, August 15th. FBR & Co cut their price target on shares of Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Thursday, August 11th.

Argos Therapeutics (NASDAQ:ARGS) opened at 4.90 on Monday. The firm’s market capitalization is $201.86 million. Argos Therapeutics has a 1-year low of $1.61 and a 1-year high of $13.97. The company has a 50-day moving average of $4.58 and a 200-day moving average of $5.31.

Argos Therapeutics (NASDAQ:ARGS) last announced its quarterly earnings results on Monday, November 14th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.03. On average, equities analysts predict that Argos Therapeutics will post ($1.56) earnings per share for the current year.

In other news, major shareholder International S. Pharmstandard bought 31,704 shares of the stock in a transaction that occurred on Friday, October 7th. The shares were acquired at an average cost of $4.73 per share, for a total transaction of $149,959.92. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder International S. Pharmstandard bought 5,580 shares of the stock in a transaction that occurred on Monday, September 19th. The shares were purchased at an average price of $4.76 per share, for a total transaction of $26,560.80. The disclosure for this purchase can be found here. 61.64% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of ARGS. Schwab Charles Investment Management Inc. purchased a new position in shares of Argos Therapeutics during the second quarter worth $137,000. California State Teachers Retirement System purchased a new position in shares of Argos Therapeutics during the second quarter worth $137,000. KCG Holdings Inc. purchased a new position in shares of Argos Therapeutics during the second quarter worth $163,000. BlackRock Investment Management LLC increased its position in shares of Argos Therapeutics by 2,162.3% in the second quarter. BlackRock Investment Management LLC now owns 39,567 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 37,818 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Argos Therapeutics by 184.5% in the second quarter. Bank of New York Mellon Corp now owns 52,215 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 33,862 shares during the last quarter. Institutional investors and hedge funds own 13.87% of the company’s stock.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

5 Day Chart for NASDAQ:ARGS

Receive News & Stock Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related stocks with our FREE daily email newsletter.